Literature DB >> 17503740

Huntington's disease: pathological mechanisms and therapeutic strategies.

Shilpa Ramaswamy1, Kathleen M Shannon, Jeffrey H Kordower.   

Abstract

Huntington's disease (HD) is a devastating neurodegenerative disorder that occurs in patients with a mutation in the huntingtin or IT15 gene. Patients are plagued by early cognitive signs, motor deficits, and psychiatric disturbances. Symptoms are attributed to cell death in the striatum and disruption of cortical-striatal circuitry. Mechanisms of cell death are unclear, but processes involving mitochondrial abnormalities, excitotoxicity, and abnormal protein degradation have been implicated. Many factors likely contribute to neuron death and dysfunction, and this has made it difficult to systematically address the pathology in HD. Pharmaceutical therapies are commonly used in patients to treat disease symptoms. These have limited benefit and do not address the inexorable disease progression. Several neuroprotective therapies are being evaluated in animal models of HD as well as in clinical trials. Similarly, cell replacement strategies such as fetal transplantation have been used in the clinic with minimal success, making future cell replacement strategies such as stem cell therapy uncertain. This review describes the disease pathology in HD and addresses many of the past and emerging therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17503740     DOI: 10.3727/000000007783464687

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  16 in total

Review 1.  Neurotrophic natural products: chemistry and biology.

Authors:  Jing Xu; Michelle H Lacoske; Emmanuel A Theodorakis
Journal:  Angew Chem Int Ed Engl       Date:  2013-12-18       Impact factor: 15.336

Review 2.  Gene therapy in mouse models of huntington disease.

Authors:  Amber L Southwell; Paul H Patterson
Journal:  Neuroscientist       Date:  2011-04       Impact factor: 7.519

3.  Family carer personal concerns in Huntington disease.

Authors:  Janet K Williams; Heather Skirton; James Jackson Barnette; Jane S Paulsen
Journal:  J Adv Nurs       Date:  2011-06-12       Impact factor: 3.187

4.  Self-paced timing detects and tracks change in prodromal Huntington disease.

Authors:  Kelly C Rowe; Jane S Paulsen; Douglas R Langbehn; Kevin Duff; Leigh J Beglinger; Chiachi Wang; Justin J F O'Rourke; Julie C Stout; David J Moser
Journal:  Neuropsychology       Date:  2010-07       Impact factor: 3.295

Review 5.  Recent progress on tissue-resident adult stem cell biology and their therapeutic implications.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Stem Cell Rev       Date:  2008       Impact factor: 5.739

6.  Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity.

Authors:  Amber L Southwell; Ali Khoshnan; Denise E Dunn; Charles W Bugg; Donald C Lo; Paul H Patterson
Journal:  J Neurosci       Date:  2008-09-03       Impact factor: 6.167

7.  IGF-1 intranasal administration rescues Huntington's disease phenotypes in YAC128 mice.

Authors:  Carla Lopes; Márcio Ribeiro; Ana I Duarte; Sandrine Humbert; Frederic Saudou; Luís Pereira de Almeida; Michael Hayden; A Cristina Rego
Journal:  Mol Neurobiol       Date:  2013-12-18       Impact factor: 5.590

8.  Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients.

Authors:  Hyemyung Seo; Woori Kim; Ole Isacson
Journal:  Hum Mol Genet       Date:  2008-07-17       Impact factor: 6.150

Review 9.  How fisetin reduces the impact of age and disease on CNS function.

Authors:  Pamela Maher
Journal:  Front Biosci (Schol Ed)       Date:  2015-06-01

10.  Human mesenchymal stem cells prolong survival and ameliorate motor deficit through trophic support in Huntington's disease mouse models.

Authors:  Yuan-Ta Lin; Yijuang Chern; Che-Kun James Shen; Hsin-Lan Wen; Ya-Chin Chang; Hung Li; Tzu-Hao Cheng; Hsiu Mei Hsieh-Li
Journal:  PLoS One       Date:  2011-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.